Stock Code: 300434
Stock Abbreviation: Golden Stone Asia Pharmaceutical
Announcement No.: 2026-024
Sichuan Golden Stone Asia Pharmaceutical Co., Ltd.
Announcement on Subsidiary's Preliminary Selection in the 12th National Centralized Drug Procurement
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and there are no false records, misleading statements, or major omissions.
Recently, Sichuan Golden Stone Asia Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") participated in the bidding for the 12th batch of national centralized drug procurement with volume-based purchasing organized by the National Joint Procurement Office (hereinafter referred to as the "Joint Procurement Office") through its wholly-owned second-level subsidiary Zhejiang Deer Pharmaceutical Co., Ltd. (hereinafter referred to as "Deer Pharmaceutical"). According to the "Announcement of Preliminary Selection Results for the 12th Batch of National Centralized Drug Procurement with Volume-Based Purchasing" issued by the Joint Procurement Office, Deer Pharmaceutical's Diclofenac Sodium Sustained-Release Tablets have been preliminarily selected in this centralized procurement with volume-based purchasing. The relevant situation is hereby announced as follows: